Cargando…

IL-17 Pathway Members as Potential Biomarkers of Effective Systemic Treatment and Cardiovascular Disease in Patients with Moderate-to-Severe Psoriasis

Psoriasis is a chronic inflammatory condition associated with atherosclerotic cardiovascular disease (CVD). Systemic anti-psoriatic treatments mainly include methotrexate and biological therapies targeting TNF, IL-12/23 and IL-17A. We profiled plasma proteins from patients with moderate-to-severe ps...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xing, Kaiser, Hannah, Kvist-Hansen, Amanda, McCauley, Benjamin D., Skov, Lone, Hansen, Peter Riis, Becker, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745093/ https://www.ncbi.nlm.nih.gov/pubmed/35008981 http://dx.doi.org/10.3390/ijms23010555

Ejemplares similares

Neutrophil Pathways of Inflammation Characterize the Blood Transcriptomic Signature of Patients with Psoriasis and Cardiovascular Disease
por: Kvist-Hansen, Amanda, et al.
Publicado: (2021)

Biomarkers of subclinical atherosclerosis in patients with psoriasis
por: Kaiser, Hannah, et al.
Publicado: (2021)

Multiscale Biology of Cardiovascular Risk in Psoriasis: Protocol for a Case-Control Study
por: Kaiser, Hannah, et al.
Publicado: (2021)

Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
por: Kvist-Hansen, Amanda, et al.
Publicado: (2019)

Statin Therapy and Vascular Inflammation Detected by Positron Emission Tomography/Computed Tomography in Patients with Psoriasis
por: KAISER, Hannah, et al.
Publicado: (2021)

Association between Vascular Inflammation and Inflammation in Adipose Tissue, Spleen, and Bone Marrow in Patients with Psoriasis
por: Kaiser, Hannah, et al.
Publicado: (2021)

Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis
por: Andersen, Clara Sophie Bramsen, et al.
Publicado: (2023)

Targeting of interleukin-17 in the treatment of psoriasis
por: Lønnberg, Ann Sophie, et al.
Publicado: (2014)

Salivary microbiota and inflammation‐related proteins in patients with psoriasis
por: Belstrøm, Daniel, et al.
Publicado: (2020)

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
por: von Stebut, Esther, et al.
Publicado: (2020)

Psoriasis and New-Onset Diabetes: A Danish nationwide cohort study
por: Khalid, Usman, et al.
Publicado: (2013)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

Traditional and Non-traditional Cardiovascular Risk Factors and Cardiovascular Disease in Women with Psoriasis
por: NÄSLUND-KOCH, Charlotte, et al.
Publicado: (2022)

The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
por: Brembilla, Nicolo Costantino, et al.
Publicado: (2018)

A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2015)

The Role of IL-17 Cytokines in Psoriasis
por: Mosca, Megan, et al.
Publicado: (2021)

Pharmacological Undertreatment of Coronary Risk Factors in Patients with Psoriasis: Observational Study of the Danish Nationwide Registries
por: Ahlehoff, Ole, et al.
Publicado: (2012)

Psoriasis Carries an Increased Risk of Venous Thromboembolism: A Danish Nationwide Cohort Study
por: Ahlehoff, Ole, et al.
Publicado: (2011)

Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2016)

The contribution of IL-17 to the development of autoimmunity in psoriasis
por: Furue, Masutaka, et al.
Publicado: (2019)

Clinical efficacy and IL-17 targeting mechanism of Indigo naturalis as a topical agent in moderate psoriasis
por: Cheng, Hui-Man, et al.
Publicado: (2017)

IL-21 Induces an Imbalance of Th17/Treg Cells in Moderate-to-Severe Plaque Psoriasis Patients
por: Shi, Yuling, et al.
Publicado: (2019)

Expression of IL-1 family members upon stimulation with IL-17 differs in keratinocytes derived from psoriasis patients and healthy donors
por: Muhr, P, et al.
Publicado: (2010)

Increased IL17A, IFNG, and FOXP3 Transcripts in Moderate-Severe Psoriasis: A Major Influence Exerted by IL17A in Disease Severity
por: de Oliveira, Priscilla Stela Santana, et al.
Publicado: (2016)

Smoking is an independent but not a causal risk factor for moderate to severe psoriasis: A Mendelian randomization study of 105,912 individuals
por: Näslund-Koch, Charlotte, et al.
Publicado: (2023)

Sarcoidosis in Patients with Psoriasis: A Population-Based Cohort Study
por: Khalid, Usman, et al.
Publicado: (2014)

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study
por: SCHWARZ, Christopher Willy, et al.
Publicado: (2021)

New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors
por: Gaspari, Anthony A, et al.
Publicado: (2015)

The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy
por: Kokolakis, Georgios, et al.
Publicado: (2022)

Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic
por: Haulrig, Morten B, et al.
Publicado: (2021)

Differentiation of IL-26(+) T(H)17 intermediates into IL-17A producers via epithelial crosstalk in psoriasis
por: Fries, Anissa, et al.
Publicado: (2023)

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
por: Blauvelt, Andrew, et al.
Publicado: (2018)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
por: Hanley, Tessa L, et al.
Publicado: (2017)

Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
por: Fargnoli, Maria Concetta
Publicado: (2019)

Treatment Preferences in Young Adults with Moderate to Severe Psoriasis: A Qualitative Study from the Nordic Countries
por: Balieva, Flora Nicol, et al.
Publicado: (2023)

Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors
por: Huang, Yu-Huei, et al.
Publicado: (2023)

Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis
por: Li, Qian, et al.
Publicado: (2022)

Association between IL-17F, IL-17RA Gene Polymorphisms and Response to Biological Drugs in Psoriasis and Beyond
por: Pușcaș, Alexandra Dana, et al.
Publicado: (2023)

Sustaining the T-cell activity in xenografted psoriasis skin
por: Christensen, Pernille Kristine Fisker, et al.
Publicado: (2023)

An Analysis of IL-10, IL-17A, IL-17RA, IL-23A and IL-23R Expression and Their Correlation with Clinical Course in Patients with Psoriasis
por: Kutwin, Magdalena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4b7c3idb4jm60ici7ol2rqc3la